- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Approved (some countries)
FDA expanded the US approval of baricitinib to adolescents aged 12 and older with severe alopecia areata in September 2026.
Hair growth rate increased 18.6-36.7% across the four formulations; total hair counts rose 4.4-8.2%; terminal (thick, visible) hair counts rose 6-7.9%; scalp coverage…
A May 2025 systematic review identified 11 clinical studies (including 2 RCTs) on exosome-based hair-loss interventions; one registered RCT (NCT06932393) was terminated…
AbbVie submitted an FDA application for upadacitinib in severe alopecia areata (adults and adolescents) in April 2026, based on the Phase 3 UP-AA program (two trials,…
A Phase 3 trial (NCT07529977) evaluating oral minoxidil (N1087) vs placebo in men with AGA was posted to ClinicalTrials.gov in April 2026. Separately, a 2026 patient…
Kintor's March 2026 annual-results disclosure reported topline data from the 666-patient Phase 3 stage of its China pivotal trial; company says it will file an NDA with…
2025-2026 peer-reviewed research described protocols for generating hiPSC-derived dermal papilla cells and testing their conditioned medium as a cell-free regenerative…
Cosmo announced positive topline Phase 3 results from two trials (1,465 patients, US and Europe) in December 2025; company plans an FDA NDA filing in early 2027 and an EU…
Kintor reported Phase 2 topline data (180 male AGA patients, QD and BIW dosing arms) showing statistically significant hair-count gains vs placebo, and said it plans to…
Nektar released topline Phase 2b REZOLVE-AA results (92 patients with severe-to-very-severe AA) in December 2025, describing a 'meaningful level of clinical effect'; full…
Activated PRP (platelets chemically triggered before injection) significantly increased hair density and reduced relapse compared with placebo. Non-activated PRP was…
For increasing hair thickness, red laser combined with LED and PRP injection ranked best (odds ratio 8.30 versus sham). For hair density, botulinum toxin plus red laser…
The spironolactone group had numerically greater increases in hair count and diameter, but the difference in hair count did not reach statistical significance. On…
In men, topical finasteride plus minoxidil ranked highly (SUCRA 80.21%), producing about 29.68 more hairs per cm² than minoxidil alone, and was statistically superior to…
Across studies, hair density increased by roughly 9.5 to 35 hairs per cm², and hair thickness improved by up to about 13 micrometers. Patient satisfaction was generally…
All active treatments beat placebo. Target-area hair count increases were: 0.01% dutasteride +32.3, 0.02% +27.5, 0.05% +75.5 hairs/cm², versus oral finasteride +41.2 and…
Pelage announced positive Phase 2a results in June 2025 (78 men and women, 4 weeks of daily dosing, 12-week follow-up) and a $120M Series B (Oct 2025, co-led by ARCH…
FDA issued a warning in April 2025 about compounded topical finasteride, citing 32 reported adverse-event cases (including low libido and erectile dysfunction) between…
A 2025 study (FASEB BioAdvances) found that verteporfin inhibition of the Hippo pathway actually reduced proliferation and stemness of hair-follicle neural crest stem…
Combined therapy significantly improved hair count (standardized mean difference 1.32) and hair diameter (SMD 0.34) compared with minoxidil alone. Doctors' visual…
Several PITX2 variants were linked to much higher odds of androgenetic alopecia: one variant (rs2200733, CT genotype) was associated with roughly 6-fold higher odds…
By month 24 (observed data), 73.5% of patients had 20% or less scalp hair loss remaining (SALT≤20) and 66.4% had 10% or less remaining; 82.4% reported meaningful overall…
No significant change in systolic blood pressure (mean difference -0.13 mmHg) or diastolic blood pressure (mean difference -1.25 mmHg). Heart rate rose slightly but…
Global telogen effluvium prevalence rose from an estimated 3.44% before the pandemic to 5.41% after it -- roughly a 1.6-fold increase. Regional rates ranged from 2.83%…
Mood changes (depressed mood, depression, and, less often, suicidal thoughts) were reported, more frequently early in treatment. Sexual dysfunction (reduced libido,…
No significant difference between groups in the frontal scalp area (P=.27). At the vertex (crown), the oral group gained 21.6% more terminal hair versus a -5.6% change…
Among week-52 responders, 90.7% (4 mg group) and 89.2% (2 mg group) still had a SALT score of 20 or less at week 104. Anxiety and depression scores remained improved…
Two-year open-label extension data presented at EADV Congress 2026 showed sustained efficacy and a safety profile consistent with prior experience through up to two years…
LLLT remains one of only three FDA-cleared approaches for AGA (alongside minoxidil and finasteride); HairMax has accumulated 8 FDA clearances across its device line. No…
Three-year data from the ALLEGRO-2b/3 long-term extension, presented at EADV 2025, showed about 90% of patients who reached SALT score <=20 at 12 months maintained that…
A 2026 systematic review (Dermatologic Therapy/Wiley) and several small randomized trials show conflicting results: some trials report increased hair density (13-20%)…
Q32 Bio announced positive 36-week topline results from Part B of the Phase 2 SIGNAL-AA trial in severe-to-very-severe AA, and said it plans to advance bempikibart into a…
Hope Medicine received US FDA clearance to begin a Phase 2 trial (180 participants, HMI-115 vs placebo over 24 weeks) after positive Phase 1b results.
Technoderma reported Phase 2a results via press release/PRNewswire describing a 4-month, 71-participant, 1:1:1 randomized trial comparing two concentrations to placebo.
A preclinical paper (PMC11180715) showed 2dDR hydrogel stimulated hair regrowth in a mouse AGA model at 80-90% of the effect of minoxidil; a human trial, 'Topical…
Despite earlier positive Phase 2 results (statistically significant increase in total follicle count vs placebo), Biosplice discontinued the dalosirvat (SM04554)…
21 treatments on one page, by condition and stage, including the ones that didn't work out.
15 studies from 2024–2026: the question, what they found, the limits and who paid.
Mouse studies, press releases and "539% better": how not to be fooled.
No JAK inhibitor was found to carry a confirmed CDSCO-approved alopecia-areata indication in India as of this research pass; baricitinib generics are sold in India but apparently for other approved indications (e.g., rheumatoid arthritis), not confirmed for AA.
This is the single most important India-specific gap identified: none of baricitinib, ritlecitinib, deuruxolitinib, or upadacitinib could be confirmed as CDSCO-approved for alopecia areata in India. Indian patients likely only have off-label/import access, if any. This should be verified directly with CDSCO's own database before publishing a definitive claim either way.
What this means today
New treatments take years to reach patients, and many fail along the way. The treatments with the strongest evidence right now are still minoxidil and, for men, finasteride; for patchy hair loss, see alopecia treatments. Don't wait for a breakthrough if your hair loss is progressing. Find your likely cause.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.